Tag: SAB Biotherapeutics
SAB Biotherapeutics awarded $57.5 to manufacture its therapeutic candidate for COVID-19
Clinical stage biopharma company SAB Biotherapeutics has been awarded $57.5 million from BARDA and the US Department of Defence for the manufacturing of SAB-185,...
Featured Article
The economic forces driving manufacturing’s next cycle
Australia’s manufacturing sector entered 2026 with improving momentum, but renewed global disruption is again testing resilience across the industry.
